The Spatial Biology Company™
New Study Shows Spatial Biology Essential for Predicting Immunotherapy Response.
A seminal study just published in JAMA Oncology determined that spatially resolved, multiplex immunofluorescence outperformed other biomarker testing approaches, such as gene expression profiling, tumor mutational burden (TMB) assessment, and immunohistochemistry (IHC), for predicting patient response to immunotherapy treatments targeting PD-1 and PD-L1. This publication is a result of an in-depth meta analysis of immuno-oncology biomarker modalities conducted by scientists at Johns Hopkins University, Yale University, Vanderbilt University, and Northwestern University. Click here to view the full details of the announcement. First author, Steve Lu, will be presenting the findings in an upcoming webinar.
- Fully customizable panels for simultaneous analysis of up to 50 biomarkers
- Sophisticated software suite for spatial characterization of tissue microenvironment
- Walk-away automation through seamless integration with existing microscopes
- Enhanced understanding of the underlying mechanisms leading to disease
- Unparalleled quantitative multiplex analysis with precise autofluorescence removal
- One platform harmonizing Opal reagents, multispectral digital pathology & scalable image analysis